ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0781

Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose

Daniel Magliulo1, Vasileios Kyttaris1 and Emily Rose2, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, West Roxbury, MA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, B-Lymphocyte, COVID-19, Infection, prevention

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior studies from our group and others showed that many patients receiving RTX have absent or numerically low antibody titers of IgG anti-SARS-CoV-2 spike after vaccination with 2 doses of the BNT162b2 or mRNA-1273 vaccines or 1 dose of Ad26.COV2.SCovid-19 vaccine. In August 2021, the CDC recommended that immunocompromised individuals receive a supplemental dose. Here, we evaluate the response to that dose.

Methods: We conducted an observational cohort study on adult patients with AIRD treated with RTX since January 2020 at our institution. Details regarding disease treatment, Covid-19 infection and vaccinations, and immunologic parameters were abstracted through chart review and telephone calls. The anti-spike protein antibodies were measured using ELISA (Attelica IM COV2G or ADVIA Centaur COV2G, Siemens, Healthineers). For statistical analysis, we used the Mann Whitney test to compare continuous variables and the chi-square test for categorical variables.

Results: Among 72 patients (median [IQR] age, 63 [54.8, 71] years), 52 (72.2%) received a supplemental Covid-19 vaccine from August 2021 to May 2022. The median (IQR) time from pre-vaccination RTX infusion to vaccination was 24 (18.5, 31) weeks. Of the 32 patients who had spike protein antibodies measured after the supplemental dose, 17 (53.1%) had detectable antibody titers. Compared to patients who had positive titers, those who were negative had lower levels of CD20 and more severe hypogammaglobinemia with lower IgM and IgG levels. Of the 22 patients who did not mount an antibody response after the original vaccine series, 8 patients (36%) had positive antibodies (seroconverted) after the supplemental dose. Patients were 15.2 times less likely to seroconvert if they had been hypergammaglobulinemic in the 12 months preceding the vaccination. There have been 21 infections in 19 patients since the beginning of the pandemic, including 11 infections after the supplemental dose. Of the 7 patients with spike antibody measurements who had Covid-19 infection at any point during the pandemic, 5 (71.4%) had positive spike antibodies. Five patients (26%) required hospitalization for their covid-19 infection, including 2 after receiving the supplemental dose. Three patients (60%) were treated in an ICU. 20 (28.6%) patients have received monoclonal antibodies pre-exposure prophylaxis, and none have had covid-19 after the prophylaxis.

Conclusion: In this single-institution study of patients receiving RTX for autoimmune rheumatic diseases, approximately 1/3 of the patients who did not initially mount an antibody response to Covid-19 vaccination, were positive after the supplemental dose. We found that hypogammaglobulinemia was a strong negative predictor of seroconversion. Breakthrough infections occurred despite vaccination. Even after infection and vaccination, some patients did not seroconvert. Approximately a quarter of RTX treated patients have received monoclonal antibodies pre-exposure prophylaxis which to date has been highly efficacious in preventing infection.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: D. Magliulo, None; V. Kyttaris, Exagen, Corbus Pharmaceuticals, Aurinia Pharmaceuticals, Scipher; E. Rose, None.

To cite this abstract in AMA style:

Magliulo D, Kyttaris V, Rose E. Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rituximab-treated-patients-with-hypogammaglobulinemia-are-less-likely-to-seroconvert-following-sars-cov-2-vaccine-supplemental-dose/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rituximab-treated-patients-with-hypogammaglobulinemia-are-less-likely-to-seroconvert-following-sars-cov-2-vaccine-supplemental-dose/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology